Previous 10 | Next 10 |
2024-06-13 13:54:33 ET More on Cerevel Therapeutics Cerevel Therapeutics: Time For A Risk Arbitrage Play? Cerevel Therapeutics gains after AbbVie says making good progress with FTC AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug ...
2024-06-13 08:25:53 ET More on AbbVie AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) AbbVie: Turnaround Lurking After The Correction Pain (Upgrade) AbbVie: This Dividend Aristocrat Is Almost Buyable Again Now Cerevel T...
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease PR Newswire - Global license agreement to focus on the development of FG-M701, a TL1A antibody, for the treatment of inflammatory bowel disease (IBD) NOR...
2024-06-12 19:12:07 ET AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 10:00 AM ET Company Participants Robert Michael - President & COO Jeffrey Stewart - EVP & Chief Commercial Officer Roopal Thakkar - SVP & C...
2024-06-12 11:30:31 ET More on Cerevel Therapeutics Cerevel Therapeutics: Time For A Risk Arbitrage Play? AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug Seeking Alpha’s Quant Rating on Cerevel Therapeutics Historical ear...
BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients PR Newswire For The Second Year, 20 Women Entrepreneurs Will Each Receive $25,000 In Funding, Plus Access to Mentorship and Community—Helping to Close the Confidence Gap ...
2024-06-11 04:33:48 ET More on Alvotech Alvotech (ALVO) Q1 2024 Earnings Call Transcript Alvotech 2024 Q1 - Results - Earnings Call Presentation Alvotech: Consider Buying As Positive Q1 Earnings Release Likely Alvotech enters $965M refinancing agreement ...
2024-06-11 00:24:03 ET Summary Baker Brothers' 13F portfolio value decreased from $8.79B to $7.97B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. Baker Brothers has had successful investments in companies that ...
2024-06-10 23:55:53 ET Summary REGENXBIO develops AAV therapies using its proprietary NAV platform, offering one-dose treatments targeting disease root causes. The company's pipeline includes promising candidates for age-related macular degeneration, Duchenne muscular dystrophy, a...
2024-06-10 13:25:30 ET Summary Aldeyra Therapeutics offers a high-risk/high-reward investment opportunity with its Reproxalap program and promising pipeline beyond Reproxalap. Reproxalap has shown positive results in preclinical and clinical trials for the treatment of dry eye dis...
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 08:25:00 ET Stocks that are trading at low- and discounted-earnings multiples can sometimes be value traps. But other times, it's just due to short-term and temporary factors that the stocks aren't doing terribly well. In these situations, there are opportunities for investors to...
2024-07-14 04:27:00 ET The broader stock market benchmarks keep reaching new heights, but the S&P 500 index's ongoing bull run has been driven heavily by its largest components. That means there are still plenty of reliable dividend-paying stocks that look like bargains. Shares ...
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis PR Newswire Submissions are supported by the Phase 3 SELECT-GCA study demonstrating upadacitinib 15 mg with a 26-week steroid taper regimen achieved the primary endp...